20

Depending on the location of the dissection, surgical intervention may be

required.

147,150 However, until a definitive diagnosis is made, the primary goal is to

reduce the BP and myocardial contractility to the lowest level compatible with the

maintenance of adequate renal, cerebral, and cardiac perfusion.

20 Aggressive BP

control is warranted to minimize target organ damage and to prevent further

dissection or hemorrhage.

146 For aortic dissection, it is suggested that the systolic BP

should be lowered to 100 to 120 mm Hg or a mean arterial pressure of less than 80

mm Hg within 5 to 10 minutes.

20

KEY REFERENCES AND WEBSITES

A full list of references for this chapter can be found at

http://thepoint.lww.com/AT11e. Below are the key references and websites for this

chapter, with the corresponding reference number in this chapter found in parentheses

after the reference.

Key References

Curran MP et al. Intravenous nicardipine: its use in the short-term treatment of hypertension and various other

indications. Drugs. 2006;66:1755. (127)

Grossman E et al. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive

emergencies and pseudoemergencies? JAMA. 1996;276:1328. (36)

Haas CE, LeBlanc JM. Acute postoperative hypertension: a review of therapeutic options. Am J Health Syst

Pharm. 2004;61:1661. (118)

Jauch EC et al; on behalf of the American Heart Association Stroke Council, Council on Cardiovascular Nursing,

Council on Peripheral Vascular Disease, and Council on Clinical Cardiology. Guidelines for the early

management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American

Heart Association/American Stroke Association. Stroke. 2013;44:870–947. (33)

Khoynezhad A, Plestis KA. Managing emergency hypertension in aortic dissection and aortic aneurysm surgery. J

Card Surg. 2006;21(Suppl 1):S3. (146)

Marik PE, Rivera R. Hypertensive emergencies: an update. Curr Opin Crit Care. 2011;17:569–580. (20)

Rodriguez M et al. Hypertensive crisis. Cardiol Rev. 2010;18:102. (3)

Key Websites

Barkis GL. Hypertensive Emergencies. Merck Manual Professional Version.

http://www.merckmanuals.com/professional/cardiovascular-disorders/hypertension/hypertensiveemergencies. Accessed October 12, 2015.

Erbel R et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. European Society of

Cardiology. http://eurheartj.oxfordjournals.org/content/ehj/35/41/2873.full.pdf. Accessed October 12,

2015.

Jauch EC et al; on behalf of the American Heart Association Stroke Council, Council on Cardiovascular Nursing,

Council on Peripheral Vascular Disease, and Council on Clinical Cardiology. Guidelines for the early

management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American

Heart Association/American Stroke Association. American Heart Association/American Stroke Association.

http://stroke.ahajournals.org/content/44/3/870. Accessed October 12, 2015.

COMPLETE REFERENCES CHAPTER 16 HYPERTENSIVE

CRISIS

Calhoun DA, Oparil S. Treatment of hypertensive crisis. N EnglJ Med. 1990;323:1177.

Ault MJ, Ellrodt AG. Pathophysiological events leading to the end-organ effects of acute hypertension. Am J

Emerg Med. 1985;3(6, Suppl):10–15.

Rodriguez M et al. Hypertensive crisis. Cardiol Rev. 2010;18:102.

Chobanian AV et al. The seventh report of the joint national committee on prevention, detection, evaluation and

treatment of high blood pressure: the JNC 7 report [published correction appears in JAMA. 2003;290(2):197].

JAMA. 2003;28:2560.

Bales A. Hypertensive crisis: how to tell if it’s an emergency or an urgency. Postgrad Med. 1999;105:119.

Vidt DG. Hypertensive crises: emergencies and urgencies. J Clin Hypertens (Greenwich). 2004;6:520.

Abo-Zena RA et al. Hypertensive urgency induced by an interaction of mirtazapine and clonidine.

Pharmacotherapy. 2000;20:476.

Patel S et al. Hypertensive crisis associated with St. John’s wort. Am J Med. 2002;112:507.

Novak BL et al. Erythropoietin-induced hypertensive urgency in a patient with chronic renal insufficiency: case

report and review of the literature. Pharmacotherapy. 2003;23:265.

Tisdale JE et al. Risk factors for hypertensive crisis: importance of out-patient blood pressure control. Fam Pract.

2004;21:420.

Mozaffarian D et al; on behalf of the American Heart Association Statistics Committee and Stroke Statistics

Subcommittee. Heart disease and stroke statistics—2015 update: a report from the American Heart

Association. Circulation. 2015;131:e29–e322.

Bender SR et al. Characteristics and management of patients presenting to the emergency department with

hypertensive urgency. J Clin Hypertens (Greenwich). 2006;8:12.

Zampaglione B et al. Hypertensive urgencies and emergencies: prevalence and clinical presentation.

Hypertension. 1996;27:144.

Bennett NM, Shea S. Hypertensive emergency: case criteria, sociodemographic profile, and previous care of 100

cases. Am J Public Health. 1988;78:636.

Shea S et al. Predisposing factors for severe uncontrolled hypertension in an inner-city minority population. N

EnglJ Med. 1992;327:776.

McRae RP Jr, Liebson PR. Hypertensive crisis. Med Clin North Am. 1986;70:749.

Bakir A, Dunea G. Accelerated and malignant hypertension: experience from a large American inner city

hospital. Int J Artif Organs. 1989;12:675.

McNair A et al. Reversibility of cerebral symptoms in severe hypertension in relation to acute antihypertensive

therapy. Acta Med Scand Suppl. 1985;693:107.

Winer N. Hypertensive crisis. Crit Care Nurs Q. 1990;13:23.

Marik PE, Rivera R. Hypertensive emergencies: an update. Curr Opin Crit Care. 2011;17:569–580.

Varon J. Treatment of acute severe hypertension. Drugs. 2008;68:283.

Norlander M et al. Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting

calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004;22:227.

Murphy C. Hypertensive emergencies. Emerg Med Clin North Am. 1995;13:973.

McKindley DS, Boucher BA. Advances in pharmacotherapy: treatment of hypertensive crisis. J Clin Pharm

Ther. 1994;19:163.

Gales MA. Oral antihypertensives for hypertensive urgencies. Ann Pharmacother. 1994;28:352.

Psaty BM et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA.

1995;274:620.

Leavitt AD, Zweifler AJ. Nifedipine, hypotension, and myocardial injury. Ann Intern Med. 1988;108:305.

O’Mailia JJ et al. Nifedipine-associated myocardial ischemia or infarction in the treatment of hypertensive

urgencies. Ann Intern Med. 1987;107:185.

Schwartz M et al. Oral nifedipine in the treatment of hypertensive urgency: cerebrovascular accident following a

single dose. Arch Intern Med. 1990;150:686.

Fami MJ et al. Another report of adverse reactions to immediate-release nifedipine. Pharmacotherapy.

1998;18:1133.

Bertel O et al. Effects of antihypertensive treatment on cerebral perfusion. Am J Med. 1987;82(3B):29.

Talbert RL. The challenge of blood management in neurologic emergencies. Pharmacotherapy. 2006;26(8 Pt

2):123S.

Jauch EC et al; on behalf of the American Heart Association Stroke Council, Council on Cardiovascular Nursing,

Council on Peripheral Vascular Disease, and Council on Clinical Cardiology. Guidelines for the early

management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American

Heart Association/American Stroke Association. Stroke. 2013;44:870–947.

Dinsdale HB. Hypertensive encephalopathy. Neurol Clin. 1983;1:3.

Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet. 2000;356:411.

Grossman E et al. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive

emergencies and pseudoemergencies? JAMA. 1996;276:1328.

Gemici K et al. Evaluation of the effect of sublingually administered nifedipine and captopril via transcranial

Doppler ultrasonography during hypertensive crisis. Blood Press. 2003;12:46.

Anderson RJ et al. Oral clonidine loading in hypertensive urgencies. JAMA. 1981;246:848.

Handler J. Hypertensive urgency. J Clin Hypertens. 2006;8:61.

Varon J, Marik PE. Clinical review: the management of hypertensive crises. Crit Care. 2003;7:374.

Reed WG, Anderson RJ. Effects of rapid blood pressure reduction on cerebral blood flow. Am Heart J.

1986;111:226.

Stewart M, Burris JF. Rebound hypertension during initiation of transdermal clonidine. Drug Intell Clin Pharm.

1988;22:573.

Vernon C, Sakula A. Fatal rebound hypertension after abrupt withdrawal of clonidine and propranolol. Br J Clin

Pract. 1979;33:112.

Damasceno A et al. Efficacy of captopril and nifedipine in black and white patients with hypertensive crisis. J

Hum Hypertens. 1997;11:471.

Misra A et al. Sublingual captopril in hypertensive urgencies. Postgrad Med J. 1993;69:498.

Komsuolu B et al. Treatment of hypertensive urgencies with oral nifedipine, nicardipine, and captopril. Angiology.

1991;42:447.

van Onzenoort HA et al. The effect of sublingual captopril versus intravenous enalaprilat on angiotensin II plasma

levels. Pharm World Sci. 2006;28:131.

Angeli P et al. Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive

emergencies. Arch Intern Med. 1991;151:678.

Wood BC et al. Oral minoxidil in the treatment of hypertensive crisis. JAMA. 1979;241:163.

Alpert MA, Bauer JH. Rapid control of severe hypertension with minoxidil. Arch Intern Med. 1982;142:2099.

McDonald AJ et al. Oral labetalol versus oral nifedipine in hypertensive urgencies. Ann Emerg Med. 1989;18:460.

Gonzalez ER et al. Dose-response evaluation of oral labetalol in patients presenting to the emergency

department with accelerated hypertension. Ann Emerg Med. 1991;20:333.

Zell-Kanter M, Leikin JB. Oral labetalol in hypertensive urgencies. Am J Emerg Med. 1991;9:136.

Atkin S et al. Oral labetalol versus oral clonidine in the emergency treatment of severe hypertension. Am J Med

Sci. 1992;303:9.

Wright SW et al. Ineffectiveness of oral labetalol for hypertensive urgency. Am J Emerg Med. 1990;8:472.

Devlin JW et al. Fenoldopam versus nitroprusside for the treatment of hypertensive emergency. Ann

Pharmacother. 2004;38:755.

Panacek E et al. Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute

severe hypertension. Fenoldopam Study Group. Acad Emerg Med. 1995;2:959.

Pilmer B et al. Fenoldopam mesylate versus sodium nitroprusside in the acute management of severe systemic

hypertension. J Clin Pharmacol. 1993;33:549.

Reisin E et al. Intravenous fenoldopam versus sodium nitroprusside in patients with severe hypertension.

Hypertension. 1990;15(2, Suppl):159.

Garwood S, Hines R. Perioperative renal preservation: dopexamine and fenoldopam: new agents to augment renal

performance. Sem Anesth Periop Med Pain. 1998;17:308.

Murphy MB et al. Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood

pressure reduction by intravenous administration of the dopamine1 agonist fenoldopam. Circulation.

1987;76:1312.

Shusterman NH et al. Fenoldopam but not nitroprusside improves renal function in severely hypertensive patients

with impaired renal function. Am J Med. 1993;95:161.

Elliott W et al. Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe

hypertension. Circulation. 1990;81:970.

McKinney TD. Management of hypertensive crisis. Hosp Pract (Off Ed). 1992;27:133.

Brater DC et al. Prolonged hemodynamic effect of furosemide in congestive heart failure. Am Heart J.

1984;4:1031.

Nitropress (sodium nitroprusside) [package insert]. Lake Forest, IL: Hospira, Inc; 2008.

Hirschl M. Guidelines for the drug treatment of hypertensive crises. Drugs. 1995;50:991.

Lavin P. Management of hypertension in patients with acute stroke. Arch Intern Med. 1986;146:66.

Schultz V. Clinical pharmacokinetics of nitroprusside, cyanide, thiosulphate and thiocyanate. Clin Pharmacokinet.

1984;9:239.

Rindone JP, Sloane EP. Cyanide toxicity from sodium nitroprusside: risks and management [published correction

appears in Ann Pharmacother. 1992;26:1160]. Ann Pharmacother. 1992;26:515.

Friederich JA, Butterworth JF 4th. Sodium nitroprusside: twenty years and counting. Anesth Analg. 1995;81:152.

Zerbe NF, Wagner BK. Use of vitamin B12

in the treatment and prevention of nitroprusside-induced cyanide

toxicity. Crit Care Med. 1993;21:465.

Robin ED, McCauley R. Nitroprusside-related cyanide poisoning: time (long past due) for urgent, effective

interventions. Chest. 1992;102:1842.

Sarvotham S. Nitroprusside therapy in post-open heart hypertensives: a ritual tryst with cyanide death. Chest.

1987;91:796.

Hall VA, Guest JM. Sodium nitroprusside-induced cyanide intoxication and prevention with sodium thiosulfate

prophylaxis. Am J Crit Care. 1992;1:19–25.

Cottrell JE et al. Prevention of nitroprusside-induced cyanide toxicity with hydroxocobalamin. N Engl J Med.

1978;298:809.

Kayser SR, Kurisu S. Hydroxocobalamin in nitroprusside-induced cyanide toxicity. Drug Intell Clin Pharm.

1986;20:365.

Curry SC, Arnold-Capell P. Toxic effects of drugs used in the ICU: nitroprusside, nitroglycerin, and angiotensin

converting enzyme inhibitors. Crit Care Clin. 1991;7:555.

Stumpf JL. Drug therapy in hypertensive crises. Clin Pharm. 1988;7:582.

Dwyer MM, Morris CL. Toxicity of sodium nitroprusside. Conn Med. 1993;57:489.

[No authors listed]. Fenoldopam—a new drug for parenteral treatment of severe hypertension. Med Lett Drugs

Ther. 1998;40:57.

Ellis D et al. Treatment of hypertensive emergencies with fenoldopam, a peripherally acting dopamine (DA1

)

receptor agonist [abstract]. Crit Care Med. 1998;26(1, Suppl):A23.

Brogden RN, Markham A. Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and

100.

101.

102.

103.

104.

105.

106.

107.

108.

109.

110.

111.

112.

113.

114.